| Literature DB >> 26327853 |
Aleksandra Andysz1, Dorota Merecz1, Aleksandra Wójcik1, Beata Świątkowska2, Kamilla Sierocka3, Anna Najder1.
Abstract
AIM OF THE STUDY: The following research is aimed at determining the effect of yoga on the quality of life of women after breast cancer surgery.Entities:
Keywords: breast cancer; mastectomy; quality of life; rehabilitation; yoga
Year: 2014 PMID: 26327853 PMCID: PMC4520362 DOI: 10.5114/pm.2014.43823
Source DB: PubMed Journal: Prz Menopauzalny ISSN: 1643-8876
Distribution of demographic variables associated with the disease and treatment in both groups and the significance of differences estimated with the use of Mann-Whitney test and Pearson's χ2
| Exercising | Non-exercising | Significance of differences (two-tailed) | |
|---|---|---|---|
| Age in years, M ± SD (Min-Max) | 54.8 ± 7.4 (43.2-66.7) | 58.6 ± 10.8 (38.9-76.5) | NS |
| Years from operation, M ± SD (Min-Max) | 5.5 ± 4.2 (2.0-15.1) | 7.6 ± 6.4 (0.5-23.7) | NS |
| Cancer location, | NS | ||
| Left breast | 5 (42) | 11 (69) | |
| Right breast | 6 (50) | 5 (31) | |
| Both breasts | 1 (8) | – | |
| Type of operation, | NS | ||
| Breast conserving surgery | 3 (25) | 3 (19) | |
| Mastectomy | 9 (75) | 13 (81) | |
| Lymph node dissection | 9 (75) | 14 (87) | |
| Type of treatment, | NS | ||
| Chemotherapy | 3 (25) | 5 (31) | |
| Hormone therapy | – | 2 (13) | |
| Chemotherapy, hormone therapy | 3 (25) | 5 (31) | |
| Radiotherapy, hormone therapy | 2 (17) | 3 (19) | |
| Radiotherapy, chemotherapy, hormone therapy | 2 (17) | 1 (6) | |
| Radiotherapy, chemotherapy, hormone therapy, immunotherapy | 1 (8) | – | |
| Participation in rehabilitation, | NS | ||
| Yes | 9 (75) | 10 (63) | |
| No | 3 (25) | 6 (37) |
Category included both women after breast conserving surgery and after mastectomy
Means, standard deviations and medians of the questionnaire scales in both groups before and after the programme
| Experimental group | Control group | |||||||
|---|---|---|---|---|---|---|---|---|
| First measurement | Second measurement | First measurement | Second measurement | |||||
| M (SD) | Me | M (SD) | Me | M (SD) | Me | M (SD) | Me | |
|
| ||||||||
| General health status and quality of life | 61.1 (12.5) | 58.3 | 72.2 (14.8) | 75 | 56.3 (20.3) | 54.2 | 55.6 (23.5) | 50 |
| Physical functioning | 84.2 (11.8) | 81.7 | 85.0 (13.4) | 86.7 | 71.1 (17.2) | 73.3 | 69.5 (17.1) | 76.7 |
| Role functioning | 90.3 (13.2) | 100 | 86.1 (25.5) | 100 | 80.2 (26.7) | 83.3 | 68.8 (27.1) | 75 |
| Emotional functioning | 58.3 (23.8) | 58.3 | 64.6 (21.7) | 66.7 | 51.4 (30.7) | 54.2 | 51.7 (29.0) | 50 |
| Cognitive functioning | 68.1 (28.8) | 75 | 75.0 (21.9) | 66.7 | 56.3 (32.1) | 50 | 61.5 (29.0) | 66.7 |
| Social functioning | 81.9 (20.7) | 83.3 | 83.3 (17.4) | 83.3 | 70.8 (26.9) | 66.7 | 63.5 (27.4) | 66.7 |
|
| ||||||||
| Fatigue | 32.4 (18.0) | 33.3 | 31.5 (18.2) | 33.3 | 43.8 (20.9) | 38.9 | 48.3 (23.4) | 44.4 |
| Nausea and vomiting | 1.4 (4.8) | 0 | 1.4 (4.8) | 0 | 30.0 (44.2) | 0 | 16.7 (28.5) | 0 |
| Pain | 13.9 (12.0) | 16.7 | 25.0 (31.4) | 16.7 | 41.7 (25.8) | 33.3 | 39.6 (25.7) | 33.3 |
| Dyspnoea | 19.4 (22.3) | 16.7 | 5.6 (13.0) | 0 | 27.1 (25.0) | 33.3 | 29.2 (31.9) | 33.3 |
| Insomnia | 44.4 (43.4) | 33.3 | 41.7 (32.2) | 33.3 | 52.1 (40.3) | 50 | 52.1 (27.1) | 66.7 |
| Appetite loss | 5.6 (13.0) | 0 | 8.3 (20.7) | 0 | 18.8 (34.4) | 0 | 18.8 (21.0) | 16.7 |
| Constipation | 19.4 (30.0) | 0 | 16.7 (22.5) | 0 | 22.2 (37.1) | 0 | 35.4 (39.4) | 16.7 |
| Diarrhoea | 5.6 (13.0) | 0 | 2.8 (9.6) | 0 | 8.3 (14.9) | 0 | 10.4 (20.1) | 0 |
| Financial difficulties | 30.6 (38.8) | 16.7 | 16.7 (22.5) | 0 | 47.9 (29.7) | 33.3 | 37.5 (31.9) | 33.3 |
|
| ||||||||
| Body image | 69.4 (21.1) | 66.7 | 76.2 (18.9) | 79.2 | 61.5 (31.8) | 66.7 | 59.9 (35.5) | 66.7 |
| Sexual functioning | 22.2 (20.5) | 25 | 26.4 (20.7) | 33.3 | 24.4 (28.8) | 16.7 | 20.0 (28.3) | 0 |
| Sexual enjoyment | 38.1 (23.0) | 33.3 | 57.1 (31.7) | 33.3 | 83.3 (18.3) | 83.3 | 75.0 (16.7) | 66.7 |
| Future prospects | 55.6 (32.8) | 66.7 | 61.1 (27.8) | 66.7 | 39.6 (30.4) | 50 | 35.4 (31.0) | 33.3 |
|
| ||||||||
| Systematic therapy side effects | 18.3 (12.8) | 14.3 | 19.4 (14.0) | 19 | 27.9 (15.0) | 28.6 | 31.3 (16.7) | 31 |
| Breast symptoms | 7.6 (7.5) | 8.3 | 4.9 (5.6) | 4.2 | 22.9 (28.9) | 8.3 | 31.6 (32.7) | 16.7 |
| Arm symptoms | 25.9 (17.9) | 27.8 | 18.5 (17.3) | 16.7 | 42.4 (24.1) | 44.4 | 43.8 (26.4) | 44.4 |
| Upset by hair loss | 100.0 (12.8) | 100 | 41.7 (16.7) | 33.3 | 37.5 (27.8) | 33.3 | 42.9 (31.7) | 33.3 |
Due to a small number of participants who answered the questions from this scale, the result was not considered in interpretation
Mean ranks and results of between-group comparisons of the results from questionnaire scales (Mann-Whitney test)
| First measurement | Second measurement | |||||
|---|---|---|---|---|---|---|
| Experimental group | Control group |
| Experimental group | Control group |
| |
|
| ||||||
| General health status and quality of life | 15.9 | 13.5 | NS | 17.6 | 11.1 | 0.033 |
| Physical functioning | 17.6 | 12.2 | NS | 19.3 | 10.9 | 0.007 |
| Role functioning | 16.1 | 13.3 | NS | 18.1 | 11.8 | 0.035 |
| Emotional functioning | 15.5 | 13.8 | NS | 16.2 | 13.2 | NS |
| Cognitive functioning | 16.4 | 13.1 | NS | 16.5 | 13.0 | NS |
| Social functioning | 16.6 | 12.9 | NS | 18.0 | 11.8 | 0.042 |
|
| ||||||
| Fatigue | 11.8 | 16.5 | NS | 11.2 | 17.0 | 0.059 |
| Nausea and vomiting | 11.0 | 16.4 | 0.027 | 11.5 | 16.7 | 0.038 |
| Pain | 8.9 | 18.7 | 0.001 | 11.4 | 16.8 | NS |
| Dyspnoea | 13.2 | 15.5 | NS | 11.0 | 17.1 | 0.025 |
| Insomnia | 13.7 | 15.1 | NS | 12.9 | 15.7 | NS |
| Appetite loss | 13.2 | 15.5 | NS | 12.1 | 16.3 | NS |
| Constipation | 13.9 | 14.1 | NS | 12.6 | 15.9 | NS |
| Diarrhoea | 13.8 | 15.0 | NS | 13.1 | 15.5 | NS |
| Financial difficulties | 11.8 | 16.5 | NS | 11.5 | 16.8 | NS |
|
| ||||||
| Body image | 15.2 | 14.0 | NS | 16.3 | 13.2 | NS |
| Sexual functioning | 14.3 | 13.8 | NS | 15.7 | 12.7 | NS |
| Sexual enjoyment | 4.4 | 10.0 | 0.007 | 5.2 | 7.4 | NS |
| Future prospects | 16.7 | 12.9 | NS | 18.0 | 11.9 | 0.037 |
|
| ||||||
| Systematic therapy side effects | 11.3 | 16.9 | NS | 11.3 | 16.9 | NS |
| Breast symptoms | 12.6 | 15.9 | NS | 9.3 | 18.4 | 0.003 |
| Arm symptoms | 11.3 | 16.9 | NS | 9.8 | 18.0 | 0.008 |
| Upset by hair loss | 8.5 | 4.6 | NS | 6.1 | 5.9 | NS |
Due to a small number of participants who answered the questions from this scale, the result was not considered in interpretation